内容概要：庞大的糖尿病患者群体带动我国胰岛素市场需求快速增长，甘精胰岛素是一种长效人胰岛素 类似物，具有长效、平稳的特点，能更好地模拟生理性基础胰岛素分泌，减少低血糖风险，在糖尿病治 疗中具有重要地位，其优势使得它在市场上具有较强的竞争力，据统计，2024年我国门甘精胰岛素行业 市场规模达60.83亿元，同比增长4.13%，占胰岛素行业整体规模的22.36%。 上市企业：甘李药业（603087）、通化东宝（600867）、联邦制药（03933.HK） 相关企业：宜昌东阳光长江药业股份有限公司、辽宁博鳌生物制药有限公司、赛诺菲（北京）制药有限 公司、江苏万邦生化医药集团有限责任公司、山东新时代药业有限公司、礼来苏州制药有限公司、合肥 天麦生物科技发展有限公司、复星万邦（江苏）医药集团有限公司 关键词：甘精胰岛素市场政策、甘精胰岛素产业链图谱、甘精胰岛素市场规模、甘精胰岛素竞争格局、 甘精胰岛素发展趋势 一、概述 甘精胰岛素（Insulin Glargine）是由大肠埃希菌通过重组DNA技术生产，主要作用是调节糖代谢，通过 促进骨骼肌和脂肪等外周组织摄取葡萄糖、抑制肝葡萄精产生而降低血糖，临床用于治疗糖尿病。 我 ...

Core Viewpoint - Tonghua Dongbao Pharmaceutical Co., Ltd. reported significant growth in revenue and profit for the first half of 2025, driven by increased sales of insulin products and successful participation in national drug procurement programs [2][3]. Company Overview and Financial Indicators - The company achieved operating revenue of approximately 1.37 billion yuan, an increase of 85.60% compared to the same period last year [2]. - Total profit reached approximately 254.93 million yuan, a significant recovery from a loss in the previous year [2]. - Net profit attributable to shareholders was approximately 217.76 million yuan, marking a turnaround from a loss in the previous year [2]. - The company’s net assets decreased by 4.11% to approximately 6.12 billion yuan, while total assets increased by 6.35% to approximately 7.85 billion yuan [2]. Industry and Main Business Situation - The company operates in the pharmaceutical manufacturing industry, focusing on drug research, production, and sales, particularly in diabetes and endocrine treatment [3][4]. - The company has a comprehensive product line for diabetes treatment, including human insulin and insulin analogs, and aims to provide integrated solutions for diabetes patients [3][4]. - The company has established a strong market presence in the diabetes treatment sector, with over 40% market share in human insulin, maintaining its position as the industry leader [9][10]. Sales and Marketing Strategy - The company has implemented a specialized sales team and marketing strategies to enhance product coverage and market penetration, particularly in hospitals [12][13]. - The company successfully secured A/A1 class procurement results for its entire insulin product line, significantly increasing its hospital access and market share [14][15]. - The company is actively expanding its international market presence, with several products already approved for sale in various countries [9][10]. Research and Development - The company is committed to innovation, focusing on the development of GLP-1 receptor agonists and other novel drugs to address unmet clinical needs in diabetes and related conditions [10][11]. - The company has multiple innovative drug candidates in various stages of clinical trials, including those targeting diabetes and gout [11][18]. - The company aims to enhance its R&D capabilities and maintain a competitive edge in the pharmaceutical market through continuous innovation [10][11].